Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5972
Gene Symbol: REN
REN
0.090 Biomarker disease BEFREE <b>Abbreviations: BP</b> = blood pressure; <b>CKD</b> = chronic kidney disease; <b>CT</b> = computed tomography; <b>ESRD</b> = end-stage renal disease; <b>FFA</b> = free fatty acid; <b>FKD</b> = fatty kidney disease; <b>GFR</b> = glomerular filtration rate; <b>MetS</b> = metabolic syndrome; <b>MRI</b> = magnetic resonance imaging; <b>NAFLD</b> = nonalcoholic fatty liver disease; <b>RAAS</b> = renin-angiotensin system; <b>SGLT2</b> = sodium-glucose cotransporter 2; <b>SNS</b> = sympathetic nervous system; <b>T2D</b> = type 2 diabetes; <b>TG</b> = triglyceride. 31013163 2019
Entrez Id: 2875
Gene Symbol: GPT
GPT
0.100 Biomarker disease BEFREE <b>Background:</b> Two facts are generally recognized: (1) development of nonalcoholic fatty liver disease (NAFLD) is consistently linked to insulin resistance which has dietary implications and (2) circulating alanine aminotransferase (ALT) levels are reasonable markers predicting NAFLD status. 31075051 2019
Entrez Id: 5950
Gene Symbol: RBP4
RBP4
0.100 Biomarker disease BEFREE <b>Conclusions:</b> RBP4 is associated with increased risk for prediabetes and MetS in obese patients with NAFLD. 31588816 2019
Entrez Id: 3605
Gene Symbol: IL17A
IL17A
0.080 AlteredExpression disease BEFREE <b>Expert opinion</b>: A recent work suggests that pro-fibrogenic cytokines, IL-17, might be important player of liver damage and even in regulation of obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD) pathogenesis. 31479282 2019
Entrez Id: 3952
Gene Symbol: LEP
LEP
0.400 AlteredExpression disease BEFREE <b>Methods:</b> A total of 203 children and adolescents aged 5-18 years were enrolled, and their anthropometric data, body composition, liver ultrasound score for NAFLD (range, 0-6), biochemical test results, and FGF-21, leptin, and adiponectin levels were analyzed. 31750276 2019
Entrez Id: 9370
Gene Symbol: ADIPOQ
ADIPOQ
0.400 AlteredExpression disease BEFREE <b>Methods:</b> A total of 203 children and adolescents aged 5-18 years were enrolled, and their anthropometric data, body composition, liver ultrasound score for NAFLD (range, 0-6), biochemical test results, and FGF-21, leptin, and adiponectin levels were analyzed. 31750276 2019
Entrez Id: 3320
Gene Symbol: HSP90AA1
HSP90AA1
0.020 AlteredExpression disease BEFREE <b>Methods:</b> In non-alcohol fatty liver disease (NAFLD) patients, as well as in diet induced obese (DIO) mice, expression of HSP90 paralogs were analyzed by immunohistochemistry and western blot. 31534518 2019
Entrez Id: 9213
Gene Symbol: XPR1
XPR1
0.100 Biomarker disease BEFREE <b>Purpose:</b> The objective of this study was to identify the role of farnesoid X receptor agonist obeticholic acid via targeting gut microbiota in NAFLD. 31308634 2019
Entrez Id: 53345
Gene Symbol: TM6SF2
TM6SF2
0.600 GeneticVariation disease BEFREE <i>TM6SF2, GCKR</i><i>,</i> and <i>MBOAT7</i> risk alleles did not show any impact on kidney function, while the <i>PNPLA3</i> G allele was associated with lower eGFR, but only in children with NAFLD (<i>p</i> = 0.003). 31505904 2019
Entrez Id: 152831
Gene Symbol: KLB
KLB
0.320 GeneticVariation disease BEFREE <i>KLB</i> rs7674434 and rs12152703 had associations with alanine aminotransferase (ALT) (<i>P</i> = 0.03 and <i>P</i> = 0.04, respectively) and gamma-glutamyltransferase (<i>P</i> = 0.03 and <i>P</i> = 0.02, respectively) levels in all subjects, but the associations were especially strong with ALT in the NAFLD group (<i>P</i> = 0.005 and <i>P</i> = 0.008, respectively). 31548436 2019
Entrez Id: 2875
Gene Symbol: GPT
GPT
0.100 GeneticVariation disease BEFREE <i>KLB</i> rs7674434 and rs12152703 had associations with alanine aminotransferase (ALT) (<i>P</i> = 0.03 and <i>P</i> = 0.04, respectively) and gamma-glutamyltransferase (<i>P</i> = 0.03 and <i>P</i> = 0.02, respectively) levels in all subjects, but the associations were especially strong with ALT in the NAFLD group (<i>P</i> = 0.005 and <i>P</i> = 0.008, respectively). 31548436 2019
Entrez Id: 3077
Gene Symbol: HFE
HFE
0.100 GeneticVariation disease BEFREE (1) Prevalence of C282Y HFE mutation was significantly higher in patients with nonalcoholic fatty liver disease compared to controls, the difference being more striking in patients with hyperferritinemia than in those without. 12779071 2003
Entrez Id: 5728
Gene Symbol: PTEN
PTEN
0.320 Biomarker disease CTD_human 1,8-Cineole Ameliorates Steatosis of Pten Liver Specific KO Mice via Akt Inactivation. 26023714 2015
Entrez Id: 3077
Gene Symbol: HFE
HFE
0.100 GeneticVariation disease BEFREE 216 patients with histological NAFLD.TMPRSS6 and HFE variants were assessed by allele specific PCR, liver histology by the NAFLD activity score and Perls' staining for iron. 23144979 2012
Entrez Id: 728441
Gene Symbol: GGT2
GGT2
0.100 Biomarker disease BEFREE 50 type 2 Egyptian diabetic patients controlled on oral hypoglycemic drugs together with 20 age- and sex-matched healthy participants were enrolled in the study; all were subjected to complete history taking, BMI, fasting plasma glucose, HOMA-IR, ALT, AST, GGT, urea and creatinine, total lipid profile, hepatitis markers including hepatitis B surface antigen and hepatitis C virus antibodies, conjugated linoleic fatty acid "CLA," and abdominal ultrasound for grading of NAFLD. 31089474 2019
Entrez Id: 2678
Gene Symbol: GGT1
GGT1
0.100 Biomarker disease BEFREE 50 type 2 Egyptian diabetic patients controlled on oral hypoglycemic drugs together with 20 age- and sex-matched healthy participants were enrolled in the study; all were subjected to complete history taking, BMI, fasting plasma glucose, HOMA-IR, ALT, AST, GGT, urea and creatinine, total lipid profile, hepatitis markers including hepatitis B surface antigen and hepatitis C virus antibodies, conjugated linoleic fatty acid "CLA," and abdominal ultrasound for grading of NAFLD. 31089474 2019
Entrez Id: 728226
Gene Symbol: GGTLC3
GGTLC3
0.100 Biomarker disease BEFREE 50 type 2 Egyptian diabetic patients controlled on oral hypoglycemic drugs together with 20 age- and sex-matched healthy participants were enrolled in the study; all were subjected to complete history taking, BMI, fasting plasma glucose, HOMA-IR, ALT, AST, GGT, urea and creatinine, total lipid profile, hepatitis markers including hepatitis B surface antigen and hepatitis C virus antibodies, conjugated linoleic fatty acid "CLA," and abdominal ultrasound for grading of NAFLD. 31089474 2019
Entrez Id: 729838
Gene Symbol: GGTLC4P
GGTLC4P
0.100 Biomarker disease BEFREE 50 type 2 Egyptian diabetic patients controlled on oral hypoglycemic drugs together with 20 age- and sex-matched healthy participants were enrolled in the study; all were subjected to complete history taking, BMI, fasting plasma glucose, HOMA-IR, ALT, AST, GGT, urea and creatinine, total lipid profile, hepatitis markers including hepatitis B surface antigen and hepatitis C virus antibodies, conjugated linoleic fatty acid "CLA," and abdominal ultrasound for grading of NAFLD. 31089474 2019
Entrez Id: 653590
Gene Symbol: GGTLC5P
GGTLC5P
0.100 Biomarker disease BEFREE 50 type 2 Egyptian diabetic patients controlled on oral hypoglycemic drugs together with 20 age- and sex-matched healthy participants were enrolled in the study; all were subjected to complete history taking, BMI, fasting plasma glucose, HOMA-IR, ALT, AST, GGT, urea and creatinine, total lipid profile, hepatitis markers including hepatitis B surface antigen and hepatitis C virus antibodies, conjugated linoleic fatty acid "CLA," and abdominal ultrasound for grading of NAFLD. 31089474 2019
Entrez Id: 80339
Gene Symbol: PNPLA3
PNPLA3
0.500 GeneticVariation disease BEFREE NAFLD predisposition runs strongly in families and an allele in the PNPLA3 gene has shown a strong association with liver steatosis and hepatic inflammation. 21178608 2011
Entrez Id: 80339
Gene Symbol: PNPLA3
PNPLA3
0.500 GeneticVariation disease BEFREE Nonalcoholic fatty liver disease (NAFLD) clusters in families, but the only known common genetic variants influencing risk are near PNPLA3. 21423719 2011
Entrez Id: 80339
Gene Symbol: PNPLA3
PNPLA3
0.500 GeneticVariation disease BEFREE Non-alcoholic fatty liver disease (NAFLD) is commonly diagnosed in patients with obesity and type 2 diabetes mellitus (T2DM), and has been associated with the single nucleotide polymorphism (SNP) rs738409 in the PNPLA3 gene. 21665509 2011
Entrez Id: 6721
Gene Symbol: SREBF2
SREBF2
0.100 GeneticVariation disease BEFREE NAFLD was associated with increased SREBP-2 maturation, HMG CoA reductase (HMGCR) expression and decreased phosphorylation of HMGCR. 22560219 2012
Entrez Id: 47
Gene Symbol: ACLY
ACLY
0.030 AlteredExpression disease BEFREE NAFLD-specific expression and methylation differences were seen for nine genes coding for key enzymes in intermediate metabolism (including PC, ACLY, and PLCG1) and insulin/insulin-like signaling (including IGF1, IGFBP2, and PRKCE) and replicated by bisulfite pyrosequening (independent n = 39). 23931760 2013
Entrez Id: 5335
Gene Symbol: PLCG1
PLCG1
0.010 AlteredExpression disease BEFREE NAFLD-specific expression and methylation differences were seen for nine genes coding for key enzymes in intermediate metabolism (including PC, ACLY, and PLCG1) and insulin/insulin-like signaling (including IGF1, IGFBP2, and PRKCE) and replicated by bisulfite pyrosequening (independent n = 39). 23931760 2013